IntelliSyn Pharma Inc.
$200,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2025-2026
- Agreement period
- September 29, 2025 – August 28, 2026
- Reference
- nrc-cnrc:172-2025-2026-Q3-1036319
Published purpose
The aim of the CIIP - UK Multisector - BT-XC-UTI project is to discover a new medicine to treat urinary tract infections. It is a collaboration between a Canadian company (IntelliSyn) with expertise in chemistry and a British company with expertise in biology (BioTryp). BioTryp has identified a bacterial protein that plays a key role in infection. IntelliSyn will design new therapeutic agents that inhibit this protein, and BioTryp will quantify the extent of inhibition in their biological assays. This iterative optimization cycle will also include drug elimination and safety optimization such that a safe, oral medicine to cure urinary tract infections can be identified.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.